Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer
Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.
Related Articles
Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer
Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast…
FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC
The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor.
Call-for-Papers | JACC: CardioOncology
Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…
Consolidation Durvalumab Improves PFS in Unresectable Stage III NSCLC Without Progression After CRT
The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.
Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate‐ and low‐risk prostate cancer
Although different adverse pathology definitions predict a higher risk of biochemical recurrence, metastasis, castrate-resistant prostate cancer, and prostate cancer–specific mortality, the absolute …
An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.
James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib…
